RXST / RxSight, Inc. (RXST) CEO Ron Kurtz on Q4 2021 Results - Earnings Call Transcript

Today we look at RxSight, Inc., a small ocular focused medical device company focused on transforming the cataract surgery market. The company is deli more_horizontal

After reaching an important support level, RxSight, Inc. (RXST) could be a good stock pick from a technical perspective. RXST surpassed resistance at more_horizontal

RxSight, Inc. (RXST) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss o more_horizontal

RxSight, Inc. (RXST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not hel more_horizontal

RxSight, Inc. (NASDAQ:RXST ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Alex Huang - Director, IR Ron Kurtz - Preside more_horizontal

RxSight, Inc. (RXST) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss o more_horizontal

Does RxSight, Inc. (RXST) have what it takes to be a top stock pick for momentum investors? Let's find out. more_horizontal

The consensus price target hints at a 25.7% upside potential for RxSight, Inc. (RXST). While empirical research shows that this sought-after metric is more_horizontal